Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Immune Therapeutics, Inc. (OTC: IMUN).

Full DD Report for IMUN

You must become a subscriber to view this report.


Recent News from (OTC: IMUN)

Immune Therapeutics Welcomes Amb. Jack Brewer to the Board of Directors
ORLANDO, Fla., Sept. 06, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC: IMUN ) ( IMUN ) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation biopharmaceutical company focused on the devel...
Source: GlobeNewswire
Date: September, 06 2018 09:30
Immune Therapeutics Labeled as a Pioneer in Forbes Article Discussing Booming Pet Care Industry
ORLANDO, Fla., Sept. 05, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE - - Immune Therapeutics, Inc. (OTCQB: IMUN), a late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, today announced...
Source: GlobeNewswire
Date: September, 05 2018 11:15
Renown HIV specialist Dr. Gary Blick Joins Immune Therapeutics Advisory Board
ORLANDO, Fla., Aug. 23, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune Therapeutics", "IMUN" or the "Company"), a late stage clinical biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, infla...
Source: GlobeNewswire
Date: August, 23 2018 09:30
Immune Therapeutics Adds Former United States Assistant Surgeon General Dr. Roscoe Moore to Board of Directors
ORLANDO, Fla., Aug. 07, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--Immune Therapeutics, Inc. (OTC: IMUN) ( IMUN ) ("Immune" “IMUN” or the "Company"), a clinical late-stage T-Cell Activation biopharmaceutical company focused on the development immunotherapies for the treatment o...
Source: GlobeNewswire
Date: August, 07 2018 08:00
Immune Therapeutics Inc Announces Publication of Peer Reviewed Scientific Paper Describing Low-Dose Naltrexone (LDN): A Promising Treatment in Immune-Related Diseases and Cancer Therapies
ORLANDO, Fla., July 25, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, infla...
Source: GlobeNewswire
Date: July, 25 2018 08:30
Research on Lodonal for HIV related GI complications featured in Plus Magazine
ORLANDO, Fla., July 19, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, infla...
Source: GlobeNewswire
Date: July, 19 2018 08:30
(CORRECTION) Immune Therapeutics Acquires 10% Stake in Cytocom; Obtains Exclusive Rights to Lodonal(TM) for Pets in United States
ORLANDO, Fla., June 05, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies for the treatment of aut...
Source: GlobeNewswire
Date: June, 05 2018 12:14
Immune Therapeutics Acquires 10% Stake in Cytocom; Obtains Exclusive Rights to Lodonal(TM) for Pets in United States
ORLANDO, Fla., June 05, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies for the treatment of aut...
Source: GlobeNewswire
Date: June, 05 2018 08:00
Immune Therapeutics, Inc. Files New Drug Application for Lodonol(TM) in Kenya to Target HIV Epidemic
ORLANDO, Fla., April 26, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, infl...
Source: GlobeNewswire
Date: April, 26 2018 08:30
Immune Therapeutics on go with late-stage study of IRT-103 in Crohn's
Immune Therapeutics ( OTCQB:IMUN -7.9% ) plans to file an application with the FDA seeking sign-off on a Phase 3 clinical trial assessing IRT-103, branded as Lodonal, for the treatment of patients at least 12 years old with moderate-to-severe Crohn's disease. The study should launch in H...
Source: SeekingAlpha
Date: March, 26 2018 12:08

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-070.00440.00570.00590.0043904,608
2018-12-060.00530.00450.00530.0045484,259
2018-12-050.00480.00530.0070.00482,553,735
2018-12-040.00480.00530.0070.00482,553,735
2018-12-030.00460.00480.00480.0043843,100

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-07384,300904,60842.4825Short
2018-12-06250,500484,25951.7285Short
2018-12-04998,9472,393,73541.7317Short
2018-12-03646,021843,10076.6245Short
2018-11-301,038,3571,859,61255.8373Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IMUN.


About Immune Therapeutics, Inc. (OTC: IMUN)

Logo for Immune Therapeutics, Inc. (OTC: IMUN)

Immune Therapeutics, Inc. is a biotechnology company developing and seeking to commercialize patented therapies in emerging nations that combat chronic, life threatening diseases by stimulating or rebalancing the immune system. Our technology platform is based on two interrelated cytokine drug therapies Low Dose Naltrexone LDN and Methionine Enkephalin MENK which work by triggering opioid receptors on immune cells to activate various cells of the immune system.

 

 

 

Current Management

  • Noreen Griffin / CEO
  • Rudy Williams / COO
    • Rudy Williams is the former president of International Engineering Services, Inc. IESINC one of the country s largest minority owned engineering service company in the early and late seventies, . He sold IES in . In the mideighties, Mr. Williams identified the need for a government affairs firm dedicated to small business issues and formed The Phoenix Group. The Phoenix Group is a public affairs company that specializes in federal government, legislative representation, and internal relations. Mr. Williams also created Direct Pharmacy Service, Inc. DPSI in the early nineties with his partner James Hill now deceased . DPSI became the largest Mail Order Pharmacy, operating from their facilities in the Southern sector of the U.S. The interface with government regulations, rules extended to DPSI to become a Pharmacy Benefit Management Company which intensified relations with federal government health care regulations. Mr. Williams has a BS/MS degree in Electrical Engineering attended Tuskegee Institute, Arizona State University and Massachusetts Institute of Technology MIT .
  • Peter Aronstam / CFO
  • Dr. Fengping Shan / Chief Scientific Officer
  • Gina Austin / General Counsel
  • Nicholas Plotnikoff / NonExecutive Chairman
  • Paul Akin /
  • Noreen Griffin /
  • Clifford A. Selsky /
  • Edward Teraskiewicz /

Current Share Structure

  • Market Cap: $11,581,633 - 03/09/2018
  • Authorized: 500,000,000 - 02/28/2018
  • Issue and Outstanding: 387,345,599 - 02/28/2018
  • Float: 7,986,000 - 12/11/2015

 


Recent Filings from (OTC: IMUN)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 27 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: April, 02 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: April, 02 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: April, 02 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: April, 02 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: April, 02 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: April, 02 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: April, 02 2018

 

 


Daily Technical Chart for (OTC: IMUN)

Daily Technical Chart for (OTC: IMUN)


Stay tuned for daily updates and more on (OTC: IMUN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: IMUN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IMUN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of IMUN and does not buy, sell, or trade any shares of IMUN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/